Blue Water Biotech Inc

Blue Water Vaccines, Inc. (BWV) operates as a biotechnology firm dedicated to the worldwide discovery and development of vaccines aimed at preventing infectious diseases. Currently in preclinical stages, their most prominent vaccine candidates are BWV-101, an influenza shot, and BWV-102, designed to counter H1 pre-pandemic threats. The company's developmental portfolio also includes other preclinical programs such as BWV-201, a vaccine addressing acute otitis media caused by Streptococcus pneumoniae; BWV-301, a combined vaccine for norovirus and rotavirus; and BWV-302, a dual-target vaccine for norovirus and malaria. Founded in 2018, BWV's operations are based in Cincinnati, Ohio.